This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Comparison With the United Kingdom, Germany, and Japan

David A. Kessler, MD, JD; Arthur E. Hass; Karyn L. Feiden; Murray Lumpkin, MD; Robert Temple, MD

JAMA. 1996;276(22):1826-1831.

Abstract
In a study reported herein, the marketing approval dates of 214 drugs newly introduced into the world market from January 1990 through December 1994 were compared in 4 countries. The analysis reveals that the United States and the United Kingdom have similar patterns of drug availability, although the United States has a number of therapies with significant public health benefits that are not yet available in the United Kingdom. The findings also show that the United States outpaces both Germany and Japan in approving important new drugs. Various strategies adopted by the Food and Drug Administration to expedite its pharmaceutical review process, including the use of industry user fees, are described.

Author Affiliations
From the Office of the Commissioner (Dr Kessler and Ms Feiden), Office of Planning and Evaluation (Mr Hass), and Center for Drug Evaluation and Research (Drs Lumpkin and Temple), Food and Drug Administration, Rockville, Md. Dr Kessler is the commissioner of the Food and Drug Administration.

Footnotes
Reprints: David A. Kessler, MD, JD, Food and Drug Administration, Office of the Commissioner, 5600 Fishers Ln, Rockville, MD 20857.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France
Wiktorowicz
Journal of Health Politics, Policy and Law 2003;28:615-658.
ABSTRACT  

Making regulation responsive to commercial interests: streamlining drug industry watchdogs * Commentary: Concern over drug industry's influence on regulatory policy in Europe * Commentary: Much ado about a good thing * Commentary: The freedom of informed choice
Abraham et al.
BMJ 2002;325:1164-1169.
FULL TEXT  

Is the FDA approving drugs too fast?
Kleinke and Gottlieb
BMJ 1998;317:899-900.
FULL TEXT